GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » ROC (Joel Greenblatt) %

Ikena Oncology (Ikena Oncology) ROC (Joel Greenblatt) % : -939.90% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ikena Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -939.90%.

The historical rank and industry rank for Ikena Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:

IKNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3818.1   Med: -915.2   Max: -647.78
Current: -885.14

During the past 5 years, Ikena Oncology's highest ROC (Joel Greenblatt) % was -647.78%. The lowest was -3818.10%. And the median was -915.20%.

IKNA's ROC (Joel Greenblatt) % is ranked worse than
65.17% of 1467 companies
in the Biotechnology industry
Industry Median: -333.73 vs IKNA: -885.14

Ikena Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Ikena Oncology ROC (Joel Greenblatt) % Historical Data

The historical data trend for Ikena Oncology's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology ROC (Joel Greenblatt) % Chart

Ikena Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-2,404.68 -3,818.10 -647.78 -813.26 -915.20

Ikena Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -704.62 -752.06 -954.69 -863.16 -939.90

Competitive Comparison of Ikena Oncology's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Ikena Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ikena Oncology's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ikena Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Ikena Oncology's ROC (Joel Greenblatt) % falls into.



Ikena Oncology ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.701) - (11.723 + 0.659 + 3.42)
=-12.101

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.197) - (7.251 + 0 + 3.396)
=-7.45

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Ikena Oncology for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-87.632/( ( (10.626 + max(-12.101, 0)) + (8.021 + max(-7.45, 0)) )/ 2 )
=-87.632/( ( 10.626 + 8.021 )/ 2 )
=-87.632/9.3235
=-939.90 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ikena Oncology  (NAS:IKNA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Ikena Oncology ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ikena Oncology (Ikena Oncology) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 101, Boston, MA, USA, 02210
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Executives
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango officer: CFO & Head of Corp. Dev. C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira officer: Principal Accounting Officer IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler director C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi director, officer: President & CEO C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier officer: Chief Business Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139